vimarsana.com

Page 7 - கிளீவ்லேண்ட் சிகிச்சையகம் லூ ருவோ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Former heavyweight champion Leon Spinks dies at 67 - Los Angeles Sentinel

Former heavyweight champion Leon Spinks dies at 67 By TIM DAHLBERG, ASSOCIATED PRESS Published February 7, 2021  In this June 12, 2011, file photo, former heavyweight boxing champion Leon Spinks waves during a Boxing Hall of Fame parade in Canastota, N.Y.  (AP Photo/Mike Groll, File) Leon Spinks, who won Olympic gold and then shocked the boxing world by beating Muhammad Ali to win the heavyweight title in only his eighth pro fight, has died. He was 67. Spinks, who lived his later years in Las Vegas, died Friday night, according to a release from a public relations firm. He had been battling prostate and other cancers.

Cleveland Clinic receives two grants to study therapeutic potential of anti-cancer drug in Alzheimer s

The National Institute of Aging, part of the National Institutes of Health, and the Alzheimer's Drug Discovery Foundation awarded five-year grants of $3.2 million and $1.4 million, respectively, to scientists from Cleveland Clinic Lou Ruvo Center for Brain Health to study the therapeutic potential of the anti-cancer drug lenalidomide in early-stage Alzheimer's disease, known as mild cognitive impairment.

NIH awards Cleveland Clinic $6 7 M to study impact of high-impact exercise in preventing Alzheimer s

 E-Mail Thursday, January 28, 2021, CLEVELAND: The National Institutes of Health has awarded Cleveland Clinic a $6.7 million grant to evaluate if high-intensity exercise can prevent development of Alzheimer s disease. The five-year study will assess the effect of home-based indoor cycling in slowing disease progression in healthy older people at high genetic risk for developing the disease. This represents the first randomized control trial to explore if a long-term exercise intervention program can alter progression of late-onset Alzheimer s disease in sedentary, high-risk individuals. If successful, the trial has the potential to provide a scalable, low-cost intervention capable of substantially reducing healthcare costs by modifying the trajectory of the disease.

Cleveland Clinic receives $6 7 million NIH grant to study high-intensity exercise as Alzheimer s prevention

Cleveland Clinic receives $6.7 million NIH grant to study high-intensity exercise as Alzheimer s prevention Contributed photo With the support of a $6.7 million NIH grant, Cleveland Clinic researchers will evaluate whether high-intensity exercise can prevent the development of Alzheimer’s disease. Cleveland Clinic has received a $6.7 million grant for a five-year study assessing the effect of home-based indoor cycling in slowing disease progression in healthy older people at high genetic risk for developing Alzheimer s disease, according to a news release. The grant, from the National Institutes of Health, supports a randomized control trial exploring whether a long-term exercise intervention program can alter progression of late-onset Alzheimer s disease in sedentary, high-risk individuals. If successful, the trial has the potential to provide a scalable, low-cost intervention that could substantially reduce health care costs by modifying the disease trajectory.

Cleveland Clinic receives two grants totaling $4 6m to study cancer drug in Alzheimer s

 E-Mail Jan. 27, 2021, Las Vegas: The National Institute of Aging (NIA), part of the National Institutes of Health (NIH), and the Alzheimer s Drug Discovery Foundation (ADDF) awarded five-year grants of $3.2 million and $1.4 million, respectively, to scientists from Cleveland Clinic Lou Ruvo Center for Brain Health to study the therapeutic potential of the anti-cancer drug lenalidomide in early-stage Alzheimer s disease, known as mild cognitive impairment (MCI). The funding will support the project Repurposing Lenalidomide for Early Alzheimer s Treatment led by Marwan Sabbagh, M.D., and Boris Decourt, Ph.D., of the Lou Ruvo Center for Brain Health. The project is comprised of two complementary clinical studies aimed at identifying whether lenalidomide reduces inflammation and other disease-related neuropathological features, and improves cognition in those living with mild cognitive impairment.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.